ClearVue signs NZ distributor for solar glass
ClearVue Technologies has appointed leading New Zealand glass manufacturer Viridian Glass, to continue the company's solar glass sales push into the Asia Pacific region.
The ASX listed company has struck a five-year manufacturing and distribution agreement that will enable Viridian to exclusively manufacture the range of ClearVue smart solar glazing products. Viridian will also pick up distribution rights for the products within the island nation.
The expansion into the NZ market strengthens the company's push into the Asia Pacific region and will meet the growing demand for energy-efficient building materials. While ClearVue is developing a range of building products, its core innovation is to turn window glass into a solar generating panel.
'This agreement represents a significant step in expanding ClearVue's presence in the region.'
ClearVue Technologies global chief executive officer Martin Deil
The new deal will provide local builders, developers and architects with energy producing products such as solar windows and building envelope 'spandrels' and cladding, to be integrated into their projects, resulting in carbon reduction and increased energy efficiency.
ClearVue Technologies global chief executive officer Martin Deil said: 'This agreement represents a significant step in expanding ClearVue's presence in the region and making our innovative solar glazing solutions more accessible to the New Zealand market. Our partnership aligns with New Zealand's strong commitment to sustainability and net-zero energy building initiatives.'
Viridian Glass is New Zealand's largest glass processor, supplying glazing solutions to both residential and commercial markets. It has a strong focus on energy efficiency and performance.
ClearVue's broader growth plan is to expand its manufacturing and distribution footprint globally. Viridian is the latest industry player to join a growing pipeline of strategic partners, which includes recently-appointed Sinrok Solar Energy in South Korea.
ClearVue's agreement with Sinrok is expected to drive sales of its smart solar glazing products to South Korea's building, construction and greenhouse sectors. The company is adopting a two-prong approach for its entry into South Korea, one of Asia's leading renewable energy-conscious nations.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
News.com.au
2 hours ago
- News.com.au
Biocurious: Inspired by Neuren, Nyrada aims to change the treatment landscape for brain and heart disorders
Nyrada is focused on a particular ion pathway to tackle disorders including stroke and traumatic brain injury Preclinical work has shown a significant reduction in secondary brain injury and cardiac damage CEO James Bonnar spent 15 years at Neuren Pharmaceuticals in the company's formative stage Nyrada (ASX:NYR) CEO James Bonnar is too modest to admit it, but he played a key role in developing and commercialising Neuren Pharmaceuticals' (ASX:NEU) neurological drug Daybue. Bonnar was one of the then New Zealand-based Neuren's first employees and spent a decade at the company, which now bears a $1.7 billion market cap. Bonnar seeks to channel Neuren's virtues as Nyrada pursues small molecule treatments for both brain and heart protection. Before Neuren, Bonnar was with Protemix, which worked on a drug for diabetes-related cardiomyopathy. 'This is not my first rodeo." Nyrada's indications of interest include traumatic brain injury (TBI), which Neuren pursued before switching development to the childhood disorder Rett syndrome. 'You learn a lot of lessons along the way, competing in both successful and unsuccessful programs,' Bonnar says. Have a nice TRPC Nyrada's lead drug was called NYR-BI03, but last week the company bestowed the 'proper' name of Xolatryp to reflect the drug's 'advancing development'. The science is based on bodily transient receptor potential canonical (TRPC) ion channels (often pronounced 'tripsy'). These conduits regulate calcium influx into cells. 'Following ischemia or injury, these ion channels are activated and let in calcium into the cell,' Bonnar says. 'That calcium builds up to the extent where they're toxic.' As with Neuren, Nyrada had a spare clinical program in its back pocket. The Delaware-incorporated Nyrada listed in 2020, having spun off from immunology play Noxopharm (ASX:NOX). Nyrada initially focused on oral inhibitors which failed preclinical toxicology studies. 'Fortunately, we had a promising secondary program, which is now the lead program," Bonnar says. Xolatryp blocks TRPC channels to protect key cells in vital organs when under stress. In the case of brain neurons, that could be after ischaemia (a blood clot) and reperfusion (the sudden flow of blood returning to an organ or tissue). Ischemic-reperfusion injury is also a key cause of tissue damage following the restoration of blood flow to the heart post-injury. It's a knock-out! Using a 'knock out' mice model, pioneering work at the University of NSW (Uni NSW) showed the rodents were protected from stroke. The 'knock out' doesn't refer to concussing the critters with a mallet, but genetically modifying and cross breeding them so they no longer express the TRPC channels. 'This confirmed that completely knocking out the channel is safe and for all intents and purposes these mice lived a normal life,' Bonnar says. Over the last 12 months, Nyrada has focused on expanding efficacy data that builds on this 'knock out' mouse work. 'We went through a few iterations of molecules that showed promise, but they weren't target specific,' Bonnar says. Let's get clinical Preclinical work suggests Xolatryp is delivering significant reduction in secondary brain injury and cardiac damage For cardiac reperfusion, rat models showed an 86% reduction in injury (there are no other approved treatments). With ischemic strokes, a mouse study showed 42% protection. The company also ran a neuroprotection study with the Walter Reed Army Institute Research and Uni NSW, deploying a TBI model. Based on follow-up magnetic resonance imaging, this showed a 'statistically significant' neuroprotective benefit. Now for a human study As they say, everything works in mice … or rats. Nyrada's attention now has turned to a phase I healthy volunteer study to appraise dosing safety. The randomised, double blinded effort involves three-hour infusions, compared with 20 hours for the first preclinical study. The study consists of three eight-patient cohorts, six on the active drug and two on the placebo in each group. Bonnar says the trial will guide the company on what indication to pursue in a phase II study. 'In each one, there is first-in-class potential with large markets and unmet need.' The company is hoping to complete the study in September. Later, the company also would like to run a TBI study in the US, given the large addressable population. 'You would struggle to do that in Australia,' Bonnar says. Tackling a barren treatment landscape Bonnar describes Xolatryp as a 'Swiss Army knife' drug candidate, in that it could have broad uses. He says the current TBI treatments only alleviate the symptoms, rather than the condition. 'It's a similar situation with ischaemic stroke, but not quite so bad.' While clot-busting drugs work effectively, they need to be administered in a narrow time window (the 60 minutes after a stroke is called the Golden Hour). Given that, they only apply to 10-15% of patients. As for cardio protection, existing drugs can reduce the ticker's workload after a heart attack, but none of them protects the heart tissue. Can Nyrada 'do a Neuren?' Despite Xolatryp's snazzy name, Nyrada faces many years and development dollars before it 'does a Neuren'. Of course, most drug developers tripsy-up before reaching the end game. Bonnar dubs TRPC as a 'hot' research area reflected in Nyrada's share price: up 68% over the last month and 160% over the last year, ascribing a $38 million market cap. 'Big Pharma is looking at cardio protection in particular and we think our novel molecule … should attract interest,' Bonnar says. At the end of March Nyrada had $4.7 million of cash, enough to fund the phase I study. 'We are pretty lean; we work as a virtual company with a low head count.' Bonnar notes Boehringer Ingelheim has developed a TRPC inhibitors for renal fibrosis, while elsewhere work is afoot to develop one for the chronic condition of cardiac hypertrophy. 'But as far as I'm aware, we are the first company to be looking at a TRPC channel blocker in the clinic in our chosen indications.'
News.com.au
14 hours ago
- News.com.au
Closing Bell: ASX powers to new 50-day high, up 0.63pc
ASX adds 52 points, hitting a new 50-day high at 8,466.70 points Broad strength with 9 of 11 sectors on the up Gold and finance stocks outperform The ASX was on a roll today, climbing swiftly in the first hour of trade and maintaining momentum throughout trade to finish up by 0.63%. That also marks a new 50-day high for the bourse, which is just 1.72% off the all-time highs reached in February this year. All but two sectors made convincing gains today, with just Consumer Discretionary (-0.11%) and Health Care (-0.37%) lagging. The ASX All Ords Gold Index outperformed once again, surging 2.46% on another lift in gold prices, which climbed 2.5% to US$3397.20 an ounce overnight. The ASX 200 Banks index also stood out, jumping 1.3%. The major four banks gained between 1.19% and 1.37%. RBA outlines tariff risks for Australian economy Speaking to the Economic Society of Australia in Brisbane today, RBA assistant governor Sarah Hunter opened with a quote from Lenin. 'There are decades where nothing happens; and there are weeks where decades happen'. It certainly feels like we've been in the tariff war trenches for years at this point, although in truth this all kicked off just four months ago. 'The broad-based nature of the proposed US tariffs, retaliation from major partners and other policy shifts all have the potential to structurally alter the world economy,' Hunter continued. The RBA has identified the key transmission channels these structural changes will flow through: Realigning trade flows between countries, production shifting to new countries over time Tariffs are likely to change consumption habits as some products become more expensive Business and consumers will become more cautious in the face of flipflopping policy, delaying major decisions involving capital investment Hunter points out that both fiscal and monetary policy can be adjusted to help offset adverse effects, and that financial markets will simply reprice assets. You can read her full speech (with sourcing and data analysis) on the RBA website, but in short Hunter concludes that we're in for a period of slower economic growth and a slightly weaker labour market. 'We also anticipate that, overall, the price of tradable goods will be slightly dampened,' Hunter said. 'Together, these two outcomes mean that inflation is forecast to be a little lower than at the February SMP, settling around the midpoint of the 2–3% target range.' While that's not good news, it's not cataclysmic either. The RBA says it will be watching its transmission channels closely from here on out, ready to adjust policy accordingly. ASX SMALL CAP LEADERS Today's best performing small cap stocks: Security Name Last % Change Volume Market Cap EPM Eclipse Metals 0.015 200% 65692044 $14,329,095 VAR Variscan Mines Ltd 0.007 40% 92864 $3,914,289 G88 Golden Mile Res Ltd 0.018 38% 10828150 $7,075,222 BYH Bryah Resources Ltd 0.015 36% 42903096 $9,569,489 BMO Bastion Minerals 0.002 33% 1803250 $1,355,441 TYX Tyranna Res Ltd 0.004 33% 2483000 $9,865,276 BCA Black Canyon Limited 0.079 30% 630241 $7,908,692 NC1 Nicoresourceslimited 0.093 27% 412715 $8,008,142 WCE Westcoastsilver Ltd 0.078 26% 5130855 $16,127,501 CAV Carnavale Resources 0.005 25% 1133878 $16,360,874 EVR Ev Resources Ltd 0.005 25% 729920 $7,943,347 GLA Gladiator Resources 0.01 25% 884127 $6,066,375 MEM Memphasys Ltd 0.005 25% 499000 $7,934,392 UNT Unith Ltd 0.01 25% 2621527 $9,830,283 WMG Western Mines 0.195 22% 65152 $14,456,535 FTL Firetail Resources 0.091 21% 4345928 $28,502,098 BTM Breakthrough Minsltd 0.12 20% 348895 $4,785,950 ALY Alchemy Resource Ltd 0.006 20% 909133 $5,890,381 AN1 Anagenics Limited 0.006 20% 100000 $2,481,602 BIT Biotron Limited 0.003 20% 2444305 $3,318,115 GGE Grand Gulf Energy 0.003 20% 439921 $7,051,062 GLL Galilee Energy Ltd 0.006 20% 416 $3,535,964 ION Iondrive Limited 0.024 20% 15264360 $23,656,727 NES Nelson Resources. 0.003 20% 2700000 $5,429,819 PRX Prodigy Gold NL 0.003 20% 5693864 $7,937,639 Making news… Eclipse Metals (ASX:EPM) unveiled a massive 89 million tonne rare earths resource at its Grønnedal project in southwest Greenland. The updated estimate shows grades averaging over 6,300ppm TREO, including high-value magnet metals like neodymium, praseodymium, dysprosium and terbium – key ingredients for EVs and wind turbines. That puts it among the highest-grade rare earth deposits in the world. This new figure is more than 70 times bigger than the previous estimate, and the mineralisation still looks to extend in every direction, said EPM. Western Yilgarn (ASX:WYX) has snapped up the Cardea 3 Bauxite Project in WA's Darling Range, just 17km from its big Julimar West deposit. It paid a modest $5k upfront, and will tip in more cash and shares once the exploration licence is granted. Previous drilling at Cardea 3 shows high-grade bauxite, with standout results like 7.5m at over 48% total alumina and low reactive silica. Nico Resources (ASX:NC1) has received firm commitments for a $1.1m placement at an 11.4% premium to its 20-day VWAP. The funding will go to exploration and development of the Wingellina nickel-cobalt project, host to 40,000t of nickel and 3000t of cobalt. Sunshine Metals (ASX:SHN) has hit bonanza-grade gold mineralisation at the Liontown prospect, with results up to 10 metres at 31.91g/t gold from 41 metres of depth. With a smaller hit of 2 metres at 121.5g/t gold in hand, SHN says the results demonstrate the historical gold mine still hosts high-grade gold mineralisation, reinforcing the company's plans to pursue shallow oxide gold production. Alchemy Resources (ASX:ALY) has taken full ownership of the Bryah iron ore project, acquiring the remaining 50% interest from Carey Mining Pty Ltd for $75,000 cash and a royalty. The gradational royalty is based on iron ore prices sold FOB from the project, ranging from $0.80 per tonne at under US$100/t of iron ore and up to $1.22 should iron prices rise above US$125/t. The gold signal is coming in loud and clear from Solstice Minerals' (ASX:SLS) Bluetooth gold prospect, part of the Yarri gold project in WA. The company has hit multiple broad intersections from less than 50 metres below surface, grading up to 20m at 2.18g/t gold. ASX SMALL CAP LAGGARDS Today's worst performing small cap stocks: Security Name Last % Change Volume Market Cap BMH Baumart Holdings Ltd 0.011 -67% 674614 $5,419,086 ADD Adavale Resource Ltd 0.001 -50% 400000 $4,574,558 OB1 Orbminco Limited 0.001 -50% 81733 $4,795,136 MGU Magnum Mining & Exp 0.005 -33% 4155608 $8,412,381 OVT Ovanti Limited 0.002 -33% 8085945 $8,380,545 RCM Rapid Critical 0.002 -33% 7719243 $3,734,834 VML Vital Metals Limited 0.002 -33% 2815666 $17,685,201 BNL Blue Star Helium Ltd 0.006 -25% 12656652 $21,559,082 MTB Mount Burgess Mining 0.003 -25% 492539 $1,406,811 NAE New Age Exploration 0.003 -25% 4402993 $10,637,596 RAN Range International 0.0015 -25% 98459 $1,878,581 UBI Universal Biosensors 0.032 -24% 841535 $12,518,832 EVEDA EVE Health Group Ltd 0.023 -23% 889655 $3,955,862 OSLDA Oncosil Medical 0.95 -21% 14356 $13,819,740 CYQ Cycliq Group Ltd 0.002 -20% 336928 $1,151,292 EV1 Evolutionenergy 0.008 -20% 2240267 $3,626,505 IMI Infinitymining 0.008 -20% 180000 $4,230,158 IS3 I Synergy Group Ltd 0.004 -20% 10000 $2,503,651 MML Mclaren Minerals 0.026 -19% 300161 $4,528,561 EXT Excite Technology 0.009 -18% 3170658 $22,799,061 HT8 Harris Technology Gl 0.009 -18% 202841 $3,618,617 CRI Criticalim 0.019 -17% 47468447 $62,041,318 ADG Adelong Gold Limited 0.005 -17% 10842256 $8,384,917 AJL AJ Lucas Group 0.005 -17% 7861 $8,254,378 ARV Artemis Resources 0.005 -17% 3120042 $15,171,176 LAST ORDERS Titanium Sands (ASX:TSL) has finalised a corporate funding solution for the Mannar heavy mineral project, whereby CPS Capital Group will provide up to $600,000 in loan funding in two tranches. The funding will be used to finalise environmental studies, advance an industrial mining licence for the project, and for general working capital. ADX Energy (ASX:ADX) has tapped David Gilbert as non-executive director, replacing John Begg as he steps down from the board of directors. Gilbert has held senior positions in companies based in Austria and Romania, locations highly relevant to ADX's operations as the company holds projects in both countries. IN CASE YOU MISSED IT MTM Critical Metals' (ASX:MTM) has achieved 98% recovery of antimony from US e-waste using its proprietary Flash Joule Heating technology. Lumos Diagnostics (ASX:LDX) has enrolled 61 of required 120 bacterial positive patients in US CLIA waiver clinical study for its point-of-care respiratory test FebriDx, designed to differentiate between bacterial and non-bacterial acute respiratory infections. Sampling at Perpetual Resources' (ASX:PEC) Igrejinha lithium project has uncovered more mineralisation ahead of RC drilling starting on June 5. essential projects unfulfilled by banks and government. Leeuwin Metals (ASX:LM1) has started phase 2 drilling at its Marda gold project to follow-up on high-grade gold intersected in the phase 1 program. Lithium Universe (ASX:LU7) is pursuing a non-binding MoU to cover full annual SC6 spodumene supply of 140,000 tonnes for its Bécancour lithium refinery in Canada. Health technology company Cardiex (ASX:CDX) has achieved an important milestone, receiving Therapeutic Goods Administration (TGA) approval for its CONNEQT Pulse arterial health monitor. Exploration is underway at Core Energy Minerals' (ASX:CR3) Grande Project in Rio Grande do Sul, Brazil, where broad uranium anomalism has been identified at surface. With gold on a bull run, Codrus Minerals (ASX:CDR) has mobilised a diamond drilling rig to investigate five targets at its Bull Run gold project in the US. Cannindah Resources' (ASX:CAE) rock chip sampling has identified two untested copper-gold porphyry targets at Mt Cannindah, with assays up to 12.28% copper and 9.94g/t gold. Everest Metals' (ASX:EMC) has delivered an engineering scoping study for rubidium extraction through a partnership with Edith Cowan University. With gold prices booming, Artemis (ASX:ARV) is lining up the drills to grow its 374,000oz gold, 64,000t copper Carlow project, with 5000 metres planned in total. Western Yilgarn (ASX:WYX) has acquired the Cardea 3 bauxite project in WA's Darling Range, which has strong potential to further increase bauxite tonnage and grade through exploration. TRADING HALTS At Stockhead, we tell it like it is. While Titanium Sands and ADX Energy are Stockhead advertisers, they did not sponsor this article.
News.com.au
14 hours ago
- News.com.au
Health Check: Don't dis-May! ASX biotechs record strong year-on-year share gains
Medadvisor and Dimerix lead the valuation gains in a choppy month Emvision and Paradigm open more pivotal trial sites Capital raisings click over MedAdvisor (ASX:MDR) is the ASX hero biotech of an otherwise subdued May, stacking on more than 52% in market capitalisation for the month. The medication compliance group said it had found a probable buyer for its Australian operations, thus spurring the rally. This supersized effort eclipsed Dimerix's (ASX:DXB) 24% surge, on the back of its May 1 news of a US distribution deal for its putative kidney disease drug. The numbers are based on Biotech Daily's top 40 index, which records the performance of the biggest stocks. The newsletter also recorded the Big Four – CSL (ASX:CSL), ResMed (ASX:RMD), ProMedicus (ASX:PME) and Cochlear (ASX:COH) – separately. Overall, the top 40 eased 2.6%, with Avita Medical (ASX:AVH) leading the decliners with a 40% tumble and Imugene (ASX:IMU) shedding 37%. shares lost 6%, translating to $555 million of lost value. Don't dis-May But don't dis-May too much: the sector's still up 9.7% year on year, just eclipsing the overall market's 9.5% increment. The Big Four gained 2.6%, thanks to Pro Medicus's 21% rebound from subdued levels. Investors had to go beyond the top 40 for the best return: pot and psychedelic drug play Incannex Healthcare (ASX:IHL) climbed 300 per cent, albeit having plunged 80% in April. We're doing better than our American friends, with the Nasdaq Biotechnology Index shedding 4.2% for the month. The index is also down 7% over the past 12 months. On trial In trial news, EMvision Medical Devices (ASX:EMV) is poised to activate its third US site in its pivotal trial of its bedside stroke detection device, Emu. The site is at The Mount Sinai Hospital in New York, a recognised leader in stroke research and treatment. The company is activating its second Australian site this week, at Sydney's Liverpool Hospital (a large stroke referral centre). These activations will bring the total of sites activated in the pivotal (validation) trial to five. These include Houston's UTHealth and Memorial Hermann-Texas Medical Centre, Mayo Clinic in Jacksonville and the Royal Melbourne Hospital. The study aims for US Food & Drug Administration (FDA) clearance for Emu, under the new device route. Knees up Paradigm Biopharmaceuticals (ASX:PAR) has activated the first of 11 proposed sites, for the local leg of its phase III knee osteoarthritis trial. Melbourne's Sportsmed Biologic is the first site, with the treatment overseen by prominent sports physician Dr Philip Bloom. The other sites are in 'various stages of start-up and activation'. Meanwhile, 48 sites are in advanced preparation stages. The study is pitched at FDA approval for Paradigm's repurposed drug candidate, to treat the common and debilitating condition. Capital-raising corner While finding a dime in the sector remains difficult, companies are managing decent smaller raisings. Shrugging off its US reimbursement setback, Pacific Edge (ASX:PEB) today upsized its NZ$15 million placement to NZ$16 million, with the board accepting oversubscriptions. A NZ$5 million share purchase plan (SPP) is yet to come. The offer is priced at NZ10 cents a share, a healthy 20% premium to the 20-day weighted average price. The raising is partly to grow sales channels for its non-invasive bladder cancer assay Cxbladder, independent of US Medicare reimbursement. Pacific Edge's Medicare coverage ceased in April, after a code pertaining to genetic oncology testing was excised. Not surpisingly, the company wants to re-gain this funding via legal and other means of suasion. Also today, Recce Pharmaceuticals (ASX:RCE) said it had placed a $7.4 million shortfall from its recent entitlement offer. This takes total proceeds from its capital raising to $15.8 million. The funds will support the synthetic anti-infective outfit's phase III trials, in Indonesia and locally. The Indonesian study treats diabetic foot infections, while the local effort is for acute bacterial skin and skin structure infections. Meanwhile heart device play Cardiex (ASX:CDX) has raised $2.4 million in an insto placement at 4 cents a share, with a $4.1 million rights issue opening on Friday. And OncoSil Medical (ASX:OSL) has raised $6.7 million in a placement and hopes an SPP will reap another $2 million. The price is one-third of a cent, a circa 20% discount. The funds will support the Oncosil's eponymous pancreatic cancer targeted radiation device. Thirty geographies have approved the tool, including Europe and the UK. Best of British biotech Data analytics house Global Data reports that venture financing for UK biopharmaceutical companies doubled in the March quarter, to US$1.1 billion. This is the highest quarterly total since 2021. This foreign investment surge also highlights danger for the Brit 'Growing dependence on US capital and policy-driven cost pressures signal an urgent need to strengthen domestic investment for sustainable growth.'
